NCT03700450已完成2 期
Cyclophosphamide As Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma. a Phase II Study (Allo-MM-PostCy-Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 3
- 主要终点
- Progression-free survival
研究概览
简要总结
The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD and progression-free survival at 2 years after after allogeneic stem cell transplantation for patients with multiple myeloma.
详细描述
The present study is a multicenter, prospective Phase II-study to evaluate the incidence of acute and chronic graft-versus-host disease at 2-years, the 2-year risk of non-relapse mortality, the 2-year progressive-free, and overall survival in patients with multiple myeloma who received a toxicity-reduced conditioning regimen combined of thiotepa and busulfan followed by allogeneic stem cell transplantation from matched or mismatched, related/unrelated and haploidentical donor, and cyclophosphamide as post-transplant GvHD prophylaxis in comparision to a historical group.
In this study will further determine toxicity and safety of cyclophosphamide as GvHD prophylaxis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Multiple myeloma newly diagnosed with deletion 17p or translocation 4;14 or multiple myeloma with
- •relapse after autologous stem cell transplantation
- •Patients age: 18 - 65 years at time of inclusion (female and male)
- •Performance status ECOG < 2
- •Availability of haploidentical, matched or mismatched related or unrelated donor
- •Patients understand and voluntarily sign an informed consent
- •The study population includes female of childbearing potential (FOCP). FOCP have to agree to comply with the applicable contraceptive requirements of the protocol as named below for the duration of the study and 6 months after end of study or having post-menopausal status or be permanently sterilized (at least 6 weeks post-sterilization).
- •Men who are sexually active with FOCP must be instructed to use male contraception (condom) in order to avoid exposure of an existing embryo/fetus. Contraception should be continued until 6 months after end of study.
排除标准
- •Severe active infection or other uncontrolled severe conditioning
- •Severe renal, hepatic, pulmonary or cardiac disease, such as:
- •Total bilirubin, SGPT or SGOT > 3 times upper the normal level
- •Left ventricular ejection fraction < 30 %
- •Creatinine clearance < 30 ml/min
- •DLCO < 35 % and/or receiving supplementary continuous oxygen
- •Positive serology for HIV
- •Pregnant or lactating women (positive serum pregnancy test)
- •Women of child-bearing potential with unclear contraception
- •Age < 18 and > 65 years.
- •Uncontrolled invasive fungal infection at time of screening (baseline)
- •Serious psychiatric or psychological disorders
- •Participation in another study with ongoing use of unlicensed investigational product from 28 days before study enrollment
研究组 & 干预措施
Cyclophosphamid post Tranplant
Experimental
Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
干预措施: Cyclophosphamide (Drug)
结局指标
主要结局
Progression-free survival
时间窗: 2 years
Progression-free survival at 2 years after allogeneic SCT
Chronic GvHD
时间窗: 2 years
Chronic GvHD at 2 years after allogeneic SCT
次要结局
- Non-relapsed mortality(2 years)
- Acute GvHD(Day +100 after allogeneic SCT)
- Chronic GvHD(1 and 2 years after allogeneic SCT)
- Toxicity of cyclophosphamide(till 2 years)
- Remission rate(till 2 years)
- Overall Survival(2 years)
- Progression-free Survival(2 years)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloid Leukemia in RemissionAdult Erythroleukemia (M6a)Adult Nasal Type Extranodal NK/T-cell LymphomaAdult Pure Erythroid Leukemia (M6b)Angioimmunoblastic T-cell LymphomaBlastic Phase Chronic Myelogenous LeukemiaChildhood Acute Erythroleukemia (M6)Childhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Myeloid Leukemia in RemissionChildhood Burkitt LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood Myelodysplastic SyndromesChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Myelomonocytic LeukemiaAnaplastic Large Cell LymphomaChronic Phase Chronic Myelogenous LeukemiaCutaneous B-cell Non-Hodgkin Lymphomade Novo Myelodysplastic SyndromesExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaPhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesSmall Intestine LymphomaSplenic Marginal Zone LymphomaStage III Multiple MyelomaTesticular LymphomaWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT01427881Fred Hutchinson Cancer Center43
尚未招募
2 期
Thalassemia study with stem cellsCTRI/2018/07/014826Christian Medical College Vellore
进行中（未招募）
1 期
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem celltransplantation for multiple myeloma. A phase II study.Multiple myelomaEUCTR2016-002557-38-DEniversity Medical Center Hamburg-Eppendorf50
终止
2 期
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCTLeukemia, Chronic MyeloidMyelodysplastic SyndromesLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativeNCT02627573St. Petersburg State Pavlov Medical University32
已完成
3 期
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic AnemiaAplastic AnemiaNCT00004474Roswell Park Cancer Institute224